← Eichor
Condition: Immune Related Colitis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immune Related Colitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-medi
Phase N/A · 4 location(s) · Meyer Children's Hospital IRCCS · NCT06862843
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Imm
Phase 2 · 9 location(s) · University of Minnesota · NCT05726396
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Phase N/A · 1 location(s) · Brain Inflammation Collaborative · NCT04806620
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Phase 2 · 2 location(s) · Shilpa Grover, MD, MPH · NCT06841705
Immune Regulation in Ulcerative Colitis or Crohn s Disease
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT00001184
KAN-004 for Immune-Related Diarrhea or Colitis
Phase 1 · 1 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT07196410
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06807593
Safety and Efficacy of Fecal Microbiota Transplantation
NA · 1 location(s) · Chinese University of Hong Kong · NCT04014413
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Phase N/A · 3 location(s) · Universidade do Porto · NCT06498167
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Im
Phase 2 · 1 location(s) · Diwakar Davar · NCT06499896
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT05663775
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.